Sanofi, Regeneron see positive results from Praluent studies
Sanofi and Regeneron Pharmaceuticals recently announced positive results from two Praluent-focused Phase 3b/4 Odyssey-DM trials involving diabetes patients. Read More »
Genentech advances adjuvant treatment for breast cancer
Genentech, a member of the Roche Group, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently announced positive results from the Phase III Aphinity study for Perjeta and Herceptin-based adjuvant treatment in combating breast cancer. Read More »
Group says Maryland law addressing pharmaceutical pricing is unconstitutional
Generic drug makers insist they attempted to work with state legislators in Maryland to carve out a bill to curb "price gouging," but they ignored the advice and passed an unconstitutional law, according to an industry group. Read More »
PCMA objects to North Dakota rules harming patient safety
Pharmaceutical Care Management Association (PCMA) recently announced that it has initiated litigation proceedings in federal court in response to a pair of state laws which it believes jeopardizes patient safety and concurrently increases prescription costs. Read More »
eFFECTOR Therapeutics presents data from its lead product candidate
eFFECTOR Therapeutics recently presented Phase 1 clinical trial data for its lead product candidate, eFT508, at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Read More »
Endo International offers Opana ER update
Endo International plc has voluntarily opted to withdraw its Opana ER (oxymorphone hydrochloride extended release) product from the market after an FDA request in June, following a thorough review period and collaboration with the agency. Read More »
McKesson reveals upgrades for online pharmacy management
McKesson Pharmacy Systems recently unveiled two new features — Medication Synchronization and Mobile Delivery — serving its pharmacy management suite, which comprises EnterpriseRx, PharmacyRx and Pharmaserv systems. Read More »
Maxor to manage pair of D.C. pharmacies for Unity Health Care
Texas-based Maxor National Pharmacy Services LLC recently unveiled two on-site pharmacy shops for Unity Health Care's Parkside and Upper Cardozo Health Centers, both with physical locations serving the community in Washington, D.C. Read More »
Endo cuts ties with Litha Healthcare Group
Endo International PLC has finalized the divestiture of Litha Healthcare Group to Acino Pharma AG. Read More »
Arena Pharmaceutical completes Phase 1 of bioavailability study
Arena Pharmaceutical Inc. has completed Phase 1 of its comparative bioavailability study on pharmacokinetic profile of extended release ralinepag in comparison to immediate release. Read More »
Meridian Bioscience releases comments concerning testing with Magellan
Meridian Bioscience Inc. released comments on a recent Food and Drug Administration Safety Notification concerning Magellan Diagnostics. Read More »
Baxter and Tel Aviv University create new licensing agreement
Baxter International Inc. and Tel Aviv University through Ramot have entered a new licensing agreement that will be assessing technologies that are being developed at the university and Tel Aviv Sourasky Medical Center. Read More »
Benznidazole for Chagas disease gains FDA clearance
KaloBios Pharmaceuticals Inc. of California, specializing in rare and neglected diseases, recently obtained FDA clearance for its oral anti-parasitic medication benznidazole designed to combat Chagas disease, a tropical malady transmitted to humans by insects. Read More »
Agile Therapeutics resubmits application for Twirla contraceptive patch
Progressive women's health care company Agile Therapeutics Inc. of Princeton, New Jersey has resubmitted its Twirla hormonal contraceptive patch to the U.S. Food and Drug Administration for a New Drug Application. Read More »
Pfizer and Merck's Type 2 diabetes drug passes primary endpoints
Pfizer Inc. and Merck released positive data from two Phase 3 studies of ertugliflozin, an investigational oral GGLT-2 inhibitor that seeks to treat Type 2 diabetes patients by improving glycemic control. Read More »
Novo Nordisk recalls cartridge holders
Novo Nordisk is recalling insulin cartridge holders of the NovoPen Echo model, warning that they may crack if they are in the presence of chemicals, such as those found in cleaners. Read More »
SteadyMed submits new drug application for Trevyent
Cardiome Pharma Corp. partner SteadyMed Ltd. has submitted a New Drug Application for Trevyent with the U.S. Food and Drug Administration. Read More »
Alexion attains support for Strensiq to address HPP
Pediatric-onset hypophosphatasia, an extremely rare metabolic disease affecting bone structure and strength, came into sharper focus recently when Alexion Pharmaceuticals won funding for its Strensiq medication from two sources via a managed access agreement. Read More »
FDA grants Biohaven's BHV-5000 orphan drug status
New Haven, Connecticut-based Biohaven Pharmaceutical Holding Company Ltd.’s BHV-5000 compound developed to treat Rett syndrome recently attained orphan drug designation from the U.S. Food and Drug Administration (FDA), its fourth product to achieve the status. Read More »
Alerts Sign-up